Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term losses lately. The San Francisco, CA-based ...

The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international ...

Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more ...

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $35.45, moving +2.12% from the previous trading session ...

Throughout 2024, Hims & Hers demonstrated consistent top-line acceleration driven by new product introductions and broader consumer adoption. The company’s revenue grew from $260 million in Q1 2024 to ...

The latest trading day saw Hims & Hers Health, Inc. (HIMS) settling at $33.05, representing a -3.09% change from its previous close.

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty ...

The stock of telehealth company Hims & Hers is experiencing a notable pullback following a period of strong performance. Investor sentiment has cooled considerably over a single week, with growing ...

In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), ...

Virtual healthcare and physician-focused digital platforms are reshaping U.S. healthcare delivery, with Hims & Hers Health, Inc. HIMS and Doximity, Inc. DOCS at the forefront. Hims & Hers operates a ...